IP Library Granted Patent US 8,324,391
Granted Patent B2
US 8,324,391 · App. 13/111,544 · Granted Dec 4, 2012

Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,324,391
App. No.
13/111,544
Granted
Dec 4, 2012
Kind
B2
Abstract

Compounds of the formula Ia***** in which the substituents have the definitions provided in the specification, are novel, effective PDE4 inhibitors.

Claims (43)

1. A compound of formula Ia*****

in which

R1 is methoxy,

R2 is methoxy, ethoxy, difluoromethoxy or 2,2-difluoroethoxy,

R3 is hydrogen,

R31 is hydrogen,

R41 is hydrogen,

R5 is hydrogen,

Har is substituted by R6 and R7, and is pyridinyl, in which

R6 is oxo, and

R7 is methyl,

or a salt of this compound.

2. A compound of formula Ia***** according to claim 1 in which

R1 is methoxy,

R2 is methoxy, ethoxy, difluoromethoxy or 2,2-difluoroethoxy,

R3 is hydrogen,

R31 is hydrogen,

R41 is hydrogen,

R5 is hydrogen,

Har is 1-methyl-1H-pyridin-2-one-5-yl,

or a salt of this compound.

3. A compound of formula Ia***** according to claim 1 in which

R1 is methoxy,

R2 is ethoxy, difluoromethoxy or 2,2-difluoroethoxy,

R3 is hydrogen,

R31 is hydrogen,

R41 is hydrogen,

R5 is hydrogen,

Har is 1-methyl-1H-pyridin-2-one-5-yl,

or a salt of this compound.

4. A compound of formula Ia***** according to claim 1 which is selected from the group consisting of

5-((2R,4aR,10bR)-9-Ethoxy-2-hydroxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)-1-methyl-1H-pyridin-2-one and a salt of this compound.

5. A compound of formula Ia***** according to claim 1 which is 5-((2R,4aR,10bR)-9-Ethoxy-2-hydroxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)-1-methyl-1H-pyridin-2-one.

6. A pharmaceutical composition comprising a compound of formula Ia***** according to claim 1 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient and/or vehicle.

7. A pharmaceutical composition comprising a compound of formula Ia***** according to claim 2 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient and/or vehicle.

8. A pharmaceutical composition comprising a compound of formula Ia***** according to claim 3 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient and/or vehicle.

9. A pharmaceutical composition comprising a compound of formula Ia***** according to claim 4 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient and/or vehicle.

10. A pharmaceutical composition comprising a compound of formula Ia***** according to claim 5 together with a pharmaceutically acceptable excipient and/or vehicle.

11. A method of treating diabetes mellitus in a patient, comprising administering to said patient a compound of formula Ia***** according to claim 1 , or a pharmaceutically acceptable salt thereof.

12. A method of treating diabetes mellitus in a patient, comprising administering to said patient a compound of formula Ia***** according to claim 2 , or a pharmaceutically acceptable salt thereof.

13. A method of treating diabetes mellitus in a patient, comprising administering to said patient a compound of formula Ia***** according to claim 3 , or a pharmaceutically acceptable salt thereof.

14. A method of treating diabetes mellitus in a patient, comprising administering to said patient a compound of formula Ia***** according to claim 4 , or a pharmaceutically acceptable salt thereof.

15. A method of treating diabetes mellitus in a patient, comprising administering to said patient a compound of formula Ia***** according to claim 5 .

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2021
From: TAKEDA GMBH
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 058043/0943 →
CHANGE OF NAME Recorded Jul 29, 2015
From: NYCOMED GERMANY HOLDING GMBH
To: TAKEDA GMBH
Reel/Frame 036205/0192 →
MERGER Recorded Jul 28, 2015
From: TAKEDA GMBH
To: NYCOMED ASSET MANAGEMENT GMBH
Reel/Frame 036193/0178 →
MERGER Recorded Jul 28, 2015
From: NYCOMED ASSET MANAGEMENT GMBH
To: NYCOMED GERMANY HOLDING GMBH
Reel/Frame 036201/0261 →
CHANGE OF NAME Recorded Mar 21, 2013
From: NYCOMED GMBH
To: TAKEDA GMBH
Reel/Frame 030062/0599 →